1.
Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019;73(5):1001-1014.e8. doi:10.1016/j.molcel.2018.11.028.
1.
Hallacli E, Kayatekin C, Nazeen S, et al. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell. 2022;185(12):2035-2056.e33. doi:10.1016/j.cell.2022.05.008.
1.
Bodea CA, Mitchell AA, Bloemendal A, Day-Williams AG, Runz H, Sunyaev SR. PINES: phenotype-informed tissue weighting improves prediction of pathogenic noncoding variants. Genome Biol. 2018;19(1):173. doi:10.1186/s13059-018-1546-6.
1.
Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease. Nat Neurosci. 2022;25(5):588-595. doi:10.1038/s41593-022-01061-1.
1.
Felsky D, Patrick E, Schneider JA, et al. Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain. Mol Neurodegener. 2018;13(1):38. doi:10.1186/s13024-018-0272-6.
1.
Hui KY, Fernandez-Hernandez H, Hu J, et al. Functional variants in the gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci Transl Med. 2018;10(423). doi:10.1126/scitranslmed.aai7795.
1.
Woodard CM, Campos BA, Kuo S-H, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep. 2014;9(4):1173-82. doi:10.1016/j.celrep.2014.10.023.